---
title: "Rare disease firm Rezolute's Q2 net loss widens"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275810372.md"
datetime: "2026-02-12T21:28:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275810372.md)
  - [en](https://longbridge.com/en/news/275810372.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275810372.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275810372.md) | [繁體中文](https://longbridge.com/zh-HK/news/275810372.md)


# Rare disease firm Rezolute's Q2 net loss widens

)

Overview

-   Rare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last year
-   R&D expenses rose to $14.3 mln due to increased clinical trial activities

Outlook

-   Rezolute to meet FDA by end of Q1 under Breakthrough Therapy Designation
-   Topline results for tumor HI study expected in H2 2026

Result Drivers

-   INCREASED R&D EXPENSES - R&D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefits

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q2 EPS -$0.22

Q2 Net -$22.77

Income mln

### Q2 -$24.22

Income mln

From

Operatio

ns

### Q2 $24.22

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 6 “strong buy” or “buy”, 4 “hold” and no “sell” or “strong sell”
-   Wall Street’s median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### 相关股票

- [Rezolute (RZLT.US)](https://longbridge.com/zh-CN/quote/RZLT.US.md)

## 相关资讯与研究

- [09:47 ETINVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)](https://longbridge.com/zh-CN/news/277955448.md)
- [Rezolute Inc. unveils presentation on late-stage therapies for hyperinsulinism and hypoglycemia](https://longbridge.com/zh-CN/news/271787706.md)
- [ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B](https://longbridge.com/zh-CN/news/278816969.md)
- [uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy?](https://longbridge.com/zh-CN/news/278556604.md)
- [ADHD May Not Be A Disorder After All](https://longbridge.com/zh-CN/news/278647785.md)